Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Halozyme TherapeuticsHALO +1.01%81 EV-to-EBIT is 22.66 as of Aug. 11, 2026, which is 25% above its 10-year median of 18.06. GuruFocus rates HALO with a GF Score™ of 81/100 and a GF Value™ of $95.64 (Fairly Valued). The stock has 4 warning signs investors should review. Among 372 Biotechnology companies, Halozyme Therapeutics ranks worse than 60.48% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Halozyme Therapeutics's Enterprise Value for the quarter that ended in Jun. 2026 was $11,403 Mil.
Halozyme Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $604 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Halozyme Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's EV-to-EBIT falls into.
Halozyme Therapeutics's current Enterprise Value is $13,679 Mil.
Halozyme Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $604 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics (HALO) has a EV-to-EBIT of 22.66 as of Aug. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Halozyme Therapeutics and its competitors. This is 25% above median its historical median of 18.06. According to the industry distribution chart, Halozyme Therapeutics ranks #225 out of 372 companies in the Biotechnology industry, placing it in the top 60.5%.
Is Halozyme Therapeutics' EV-to-EBIT too high?
Halozyme Therapeutics' current EV-to-EBIT of 22.66 is 25% above median its 10-year median of 18.06. The Biotechnology industry median EV-to-EBIT is 15.09. Halozyme Therapeutics' value of 22.66 is 50.2% above this industry median. Based on the distribution chart, Halozyme Therapeutics ranks #225 out of 372 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Halozyme Therapeutics has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' EV-to-EBIT compare to NUVL and KRYS?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #225 out of 372 companies for EV-to-EBIT. This places Halozyme Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 15.09. Halozyme Therapeutics' value of 22.66 is 50.2% above this benchmark. While the company's 10-year median is 18.06 vs. the industry median of 15.09, Halozyme Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.09, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Halozyme Therapeutics's current EV-to-EBIT of 22.66 is 50.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Halozyme Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Halozyme Therapeutics's current EV-to-EBIT is 22.66, which is 25% above median its own 10-year median of 18.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Fairly Valued. The stock's GF Value™ is $95.64, compared to a current price of $103.64 — trading 8.4% above its estimated fair value. The current EV-to-EBIT is 22.66, which is 25% above median its 10-year median of 18.06 and 50.2% above the Biotechnology industry median of 15.09. Halozyme Therapeutics' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current EV-to-EBIT is 22.66 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be overvalued.
The current stock price of $103.64 is trading 8.4% above its estimated GF Value™ of $95.64.
GuruFocus considers Halozyme Therapeutics to be Fairly Valued.
Key valuation signals for HALO:
EV-to-EBIT: 22.66 (25% above median its 10-year median of 18.06)
GF Value™: $95.64 vs. price of $103.64 (8.4% above fair value)
Industry Position: 50.2% above the Biotechnology median (#225 of 372)
No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
81GF Score
Get the complete analysis for HALO
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HALO has been successfully added to your 
